Journal article

A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals

SL Pett, LA Williams, RO Day, AR Lloyd, AD Carr, KR Clezy, S Emery, E Kaplan, DA McPhee, AJ McLachlan, FB Gelder, SR Lewin, W Liauw, KM Williams

HIV CLINICAL TRIALS | TAYLOR & FRANCIS LTD | Published : 2004

Abstract

PURPOSE: To establish the pharmacokinetics and safety of single-dose polyclonal caprine anti-HIV antibodies ((PE)HRG214)in HIV-1-infected individuals. DESIGN: A phase 1, open-label, nonrandomized, dose-escalating study. METHOD: HIV-1-infected patients with CD4+ T-cell counts of or =5,000 copies/mL received a single intravenous dose of HRG. Dosing began at 6,000 U/kg HRG with proposed step-wise escalation to 96,000 U/kg. RESULTS: Eleven males were enrolled; median CD4+T-cell count and VL were 96 cells/microL and 126,200 copies/mL, respectively. HRG exhibited linear pharmacokinetics across the dosing range studied. The mean terminal elimination half-life (t(1/2)) was 136.6 +/- 44.6 hours (ran..

View full abstract

University of Melbourne Researchers